Process of discontinuation | 3.41 (0.37) | 3.45 | 3.36 | 0.25 |
Individual dose-reduction schedule (#22) | 4.23 (0.96) | 4.43 | 3.96 | 0.49d |
Relapse prevention (#50) | 4.20 (1.04) | 4.27 | 4.11 | 0.15 |
Provide information about withdrawal symptoms (#17) | 4.09 (1.04) | 3.95 | 4.30 | 0.35 |
Fear of relapse (#11) | 4.00 (1.10) | 4.03 | 3.96 | 0.07 |
Time period and rate of dose reduction (phasing of the dosage) (#23) | 3.86 (1.34) | 4.00 | 3.67 | 0.25 |
Signalling plan: Which situations do not go so well, what happens, what can you do about it? (#18) | 3.69 (1.08) | 3.51 | 3.93 | 0.40 |
What options are there if things do not go well after you stop? (#19) | 3.63 (1.18) | 3.84 | 3.33 | 0.44 |
You can start again, if you are not able to cut back/it is OK if you cannot stop/you have not failed if you change your mind (#20) | 3.52 (1.18) | 3.41 | 3.67 | 0.23 |
How to continue without antidepressants, offer alternatives (#47) | 3.48 (1.30) | 3.51 | 3.44 | 0.05 |
What is needed to build up the patient’s personal strengths? (#48) | 3.28 (1.29) | 3.27 | 3.30 | 0.02 |
What would your life look like without medication? (#10) | 2.81 (1.26) | 3.14 | 2.37 | 0.64d |
The patient’s expectations about the role of their GP (#41) | 2.73 (1.10) | 2.89 | 2.52 | 0.35 |
Other therapeutic options (#46) | 2.64 (1.29) | 2.57 | 2.74 | 0.13 |
Possible (temporary) alternative medication (such as sleep medication) (#45) | 2.59 (1.15) | 2.68 | 2.48 | 0.17 |
Explanation of tapering strips (if available) (#24) | 2.34 (1.43) | 2.19 | 2.56 | 0.26 |
Expectations | 3.35 (0.56) | 3.28 | 3.45 | 0.31 |
Previous experiences with dose reduction (#21) | 3.95 (1.08) | 3.78 | 4.19 | 0.39 |
Advantages and disadvantages of discontinuing antidepressants (#3) | 3.91 (1.15) | 4.03 | 3.74 | 0.25 |
Expectations: What do you hope to achieve? (#1) | 3.77 (1.14) | 3.65 | 3.93 | 0.25 |
The guideline of the Dutch College of General Practitioners: What does it say about antidepressants? (#49) | 1.78 (1.03) | 1.65 | 1.96 | 0.29 |
Professional guidance | 3.34 (0.59) | 3.47 | 3.15 | 0.56d |
Regular counselling sessions to provide guidance (check-ups) (#43) | 3.86 (1.10) | 4.00 | 3.67 | 0.30 |
Supervision: Who is going to supervise the dose reduction? (#39) | 3.58 (1.22) | 3.65 | 3.48 | 0.14 |
How quickly can the person providing counselling be contacted? (#44) | 3.56 (1.20) | 3.59 | 3.52 | 0.06 |
What support would help you reduce your medication? (#9) | 3.48 (1.23) | 3.59 | 3.33 | 0.21 |
Option of accompanying counselling sessions with, for example, a psychologist (#42) | 2.95 (1.30) | 3.15 | 2.19 | 1.21e |
Sessions with POH-GGZ (GP support division of the Dutch Mental Healthcare Association) (#40) | 2.58 (1.31) | 2.46 | 2.74 | 0.22 |
Current use | 3.28 (0.47) | 3.21 | 3.36 | 0.32 |
Current effect. What effect do you notice of the medicine (that is, calm, balanced, flat) and what do you think of that? (#12) | 3.84 (1.07) | 3.65 | 4.11 | 0.44 |
Reason(s) to stop taking antidepressants (#4) | 3.84 (1.19) | 3.65 | 4.11 | 0.40 |
Current side effects of medication (#13) | 3.67 (1.20) | 3.54 | 3.85 | 0.26 |
Advantages and disadvantages of using antidepressants (#2) | 3.52 (1.17) | 3.59 | 3.41 | 0.15 |
Other medication and possible interaction with antidepressants (#32) | 3.33 (1.21) | 3.30 | 3.37 | 0.06 |
How many previous depressive episodes has the patient had? (#37) | 3.05 (1.40) | 2.84 | 3.33 | 0.35 |
Meaning of ADM in your life (#7) | 2.97 (1.17) | 3.00 | 2.93 | 0.06 |
Why was the patient initially prescribed ADM, original indication(depression, anxiety, other reasons) (#36) | 2.95 (1.34) | 3.14 | 2.70 | 0.32 |
Attribution: What according to the patient caused the complaint(s)? (#5) | 2.84 (1.34) | 2.54 | 3.26 | 0.57d |
Duration of ADM use: How long has the patient been using antidepressants? (#38) | 2.73 (1.16) | 2.89 | 2.52 | 0.32 |
Environment | 2.67 (0.58) | 2.68 | 2.66 | 0.03 |
Ensure stable life circumstances during reduction (no life event) (#26) | 3.48 (1.17) | 3.57 | 3.37 | 0.17 |
Involve partner and social environment (#29) | 3.28 (1.02) | 3.11 | 3.52 | 0.41 |
Can patients count on support from social environment if they struggle? (#31) | 3.16 (1.12) | 3.11 | 3.22 | 0.10 |
Attitude of the social environment (partner, friends, colleagues) towards reduction or use of antidepressants (#28) | 2.41 (1.15) | 2.24 | 2.63 | 0.34 |
Situation at work (#27) | 2.05 (1.06) | 2.32 | 1.67 | 0.64d |
Suitable time of year (#25) | 1.64 (0.88) | 1.70 | 1.56 | 0.16 |
Side effects | 2.52 (0.53) | 2.49 | 2.56 | 0.13 |
Current quality of life and psychological functioning (#6) | 3.98 (1.03) | 4.16 | 3.74 | 0.41 |
Suicidality (#8) | 3.80 (1.30) | 3.54 | 4.15 | 0.49 |
Problems with emotions (emotional blunting) (#16) | 3.05 (1.10) | 3.27 | 2.74 | 0.50d |
Genetic vulnerability for depression (#30) | 2.41 (1.37) | 2.59 | 2.15 | 0.33 |
Problems with sexuality (#14) | 2.36 (1.13) | 2.32 | 2.41 | 0.08 |
Addiction(s) (#34) | 1.95 (1.15) | 1.68 | 2.33 | 0.57c |
Problems with weight (#15) | 1.92 (1.03) | 1.81 | 2.07 | 0.25 |
Chance of falls: Has patient ever had a fall? (#33) | 1.52 (0.82) | 1.32 | 1.78 | 0.56c |
Smoking and/or drinking (#35) | 1.70 (1.17) | 1.73 | 1.67 | 0.06 |